The current price of CRSP is $48.11 — it has decreased by 7.09% since the previous close. Data as of Nov 5, 2026.
CRSP is down 10.10% over the past week, down 16.48% over the past month and down 15.97% over the past year. The price is below its 200-day moving average of $52.84.
Analysts' average 12-month price target for CRSP is $64.14, which implies 33.33% upside from the current price. Individual estimates range from $52.00 to $80.00.
Of the 23 analysts covering CRISPR Therapeutics AG, 4 rate it a strong buy, 9 rate it a buy and 10 rate it a hold. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.
CRISPR Therapeutics AG has a market capitalization of $4.67B. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.
In its most recent quarterly report, CRISPR Therapeutics AG posted a loss of $1.15 per share against an estimate of -$1.04, missing expectations by 10.58%. Upcoming reports are listed in the earnings calendar.
CRISPR Therapeutics AG reported revenue of $12.67M in its most recent quarter, which has increased by 1,325.08% compared with the same quarter a year earlier. Analysts had expected $14.75M.
Companies most comparable to CRISPR Therapeutics AG include Beam Therapeutics Inc., Intellia Therapeutics, Inc., Ginkgo Bioworks Holdings, Inc., REGENXBIO Inc. and Editas Medicine, Inc.
In the latest trading session CRSP moved between $47.94 and $51.21, a range of 6.80% of its current price.
Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of CRISPR Therapeutics AG shows a strong sell rating today and a strong sell rating on the weekly timeframe. Market conditions change quickly, so it is worth looking further ahead as well — the 1-month rating for CRISPR Therapeutics AG is strong sell. Technical ratings are indicators, not investment advice.
Over the past 52 weeks CRSP has traded between $44.12 and $63.45. The current price is 24.18% below its 52-week high.
Figures as of Nov 5, 2026. This information is provided for general purposes only and is not investment advice.